Stock exchange releases

Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Apr 23, 2025
Nightingale Health’s laboratory implementation in the United States progresses as planned – opens first to medical research customers in Summer 2025 – Apr 10, 2025
Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US – Mar 21, 2025
Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025 – Mar 18, 2025
The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus – Mar 17, 2025
Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US – Mar 17, 2025
Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki – Mar 12, 2025
Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States – Mar 06, 2025
Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025 – Feb 28, 2025
Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks – Feb 27, 2025
Nightingale Health announces its updated regulatory plan in the United States – Feb 07, 2025
Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region – Jan 27, 2025
Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States – Jan 23, 2025
Conversion of Nightingale Health Plc’s EMP shares to Series B shares – Dec 23, 2024
Nightingale Health Plc – Managers’ Transactions – Olli Karhi – Dec 20, 2024
Nightingale Health Plc appoints Lago Kapital as liquidity provider – Dec 18, 2024
Nightingale Health Plc: Subscription of Series B shares with option rights – Dec 13, 2024
Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality – Dec 04, 2024
Nightingale Health announces opening of its Singapore laboratory – Nov 29, 2024
Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S. – Nov 27, 2024
Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore – Nov 14, 2024
Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc – Nov 08, 2024
Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer – Nov 06, 2024
Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale’s Health Check in the US – Oct 30, 2024
Notice to the Annual General Meeting of Nightingale Health Plc – Oct 10, 2024
Nightingale Health’s Annual Report for financial year 2023–2024 has been published – Oct 10, 2024
Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Oct 09, 2024
Nightingale Health’s Board of Directors resolved on amendment to CEO’s incentive program – Sep 20, 2024
Nightingale Health Plc Financial Statements Release 1 July 2023 – 30 June 2024 – Sep 20, 2024
Nightingale Health receives third regulatory approval for healthcare use from Health Sciences Authority in Singapore – Sep 19, 2024
Nightingale Health to publish Financial Statements Release for financial year July 2023 – June 2024 on 20 September 2024 – Sep 05, 2024
Nightingale Health attains UKCA marking for its blood analysis technology to bring its technology to healthcare use in the United Kingdom – Aug 20, 2024
Nightingale Health receives additional regulatory approval for healthcare use from Health Sciences Authority in Singapore – Aug 20, 2024
Nightingale Health and U.S.-based Phenome Health announce a partnership to strive towards the most transformational change in the history of healthcare – Aug 06, 2024
Nightingale Health Plc – Managers’ transactions – Olli Karhi – Jul 04, 2024
Summary of Financial Year 7/2023 - 6/2024: Nightingale Health achieved several breakthroughs in adopting the company’s technology in healthcare – Jul 03, 2024
Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel – Jun 28, 2024
Inside information: Nightingale Health and Boston Heart Diagnostics enter strategic partnership to sell Nightingale’s Health Check in the United States – Jun 28, 2024
Nightingale Health and ZOE expand research collaboration to include self-collected blood samples – Jun 27, 2024
Nightingale Health acquires all intellectual property assets of the Velvet™ blood collection device and secures its position as the sole provider of a fully integrated remote health check solution – Jun 27, 2024
Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy) – Jun 18, 2024
Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Pasi Soininen) – Jun 18, 2024
Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna) – Jun 18, 2024
Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas) – Jun 18, 2024
Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Jun 11, 2024
Health check based on advanced blood analysis technology builds a better foundation for public health – Jun 06, 2024
Nightingale Health’s Board of Directors extended the subscription period of employee option rights – May 23, 2024
Nightingale Health launches new website aligned with the B2B and B2G strategy – May 21, 2024
Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million – Apr 25, 2024
Nightingale Health to establish a laboratory in the United States with Weill Cornell Medicine as the first customer – Apr 16, 2024
Supplement to the release: Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc. – Apr 12, 2024
Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc. – Apr 12, 2024
Nightingale Health has completed the acquisition of Welltus Inc – Mar 29, 2024
Correction: Conversion of Nightingale Health Plc’s EMP shares to Series B shares – Mar 21, 2024
Conversion of Nightingale Health Plc’s EMP shares to Series B shares – Mar 20, 2024
Nightingale Health’s technology used to analyze Uganda’s General Population Cohort (GPC) – Mar 19, 2024
Supplement to the release: Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc – Mar 07, 2024
Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc – Mar 07, 2024
Nightingale Health’s Half-year report: Healthcare implementations progressing in Finland and Singapore – Mar 07, 2024
Nightingale Health to publish half-year report for July – December 2023 on 7 March 2024 – Feb 28, 2024
Nightingale Health receives regulatory approval for healthcare use from Health Sciences Authority in Singapore – Feb 23, 2024
Nightingale Health receives five new patents for its proprietary health risk detection capability – Jan 31, 2024
Nightingale Health joins Radical Health Festival Helsinki as Founding Partner to promote urgent global need for preventative health – Jan 19, 2024
Terveystalo begins using Nightingale Health’s blood analysis technology in regular health checks in occupational health – Jan 02, 2024
Nightingale Health completes the analysis of all 500,000 UK Biobank samples creating the world's largest blood biomarker database for chronic disease research and prevention – Dec 13, 2023
Change in Nightingale Health Plc’s Management Team – Nov 27, 2023
Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc – Nov 16, 2023
Inside information: Nightingale Health and Innoquest Diagnostics enter into collaboration agreement to make Nightingale Health’s technology accessible in the Southeast Asia region – Nov 15, 2023
Research study abstract by Nightingale Health on heart disease prevention wins American Heart Association’s Paul Dudley White International Scholar Award – Nov 01, 2023
Notice to the Annual General Meeting of Nightingale Health Plc – Oct 19, 2023
Nightingale Health’s Annual Report for financial year 2022–2023 has been published – Oct 19, 2023
Nightingale Health Plc – Managers’ transactions – Ilkka Laurila – Oct 17, 2023
Nightingale Health’s Board of Directors resolved on new share-based incentive programs and amendments to existing incentive programs – Oct 16, 2023
Nightingale Health Plc – Managers’ transactions – Tuukka Paavola – Oct 02, 2023
Nightingale Health Plc Financial Statements Release 1 July 2022 – 30 June 2023 – Sep 28, 2023
Nightingale Health receives three new patents further strengthening its IP portfolio – Sep 26, 2023
Nightingale Health’s laboratory in the United Kingdom to be situated in Porton Science Park – Sep 19, 2023
Nightingale Health to publish Financial Statements Release for financial year July 2022–June 2023 on 28 September 2023 – Sep 14, 2023
Inside information: Nightingale Health updates its strategy with a focus on B2B and B2G markets – Sep 11, 2023
Nightingale Health to provide blood sample analysis service for a large U.S. healthcare system – Sep 06, 2023
Inside information: Terveystalo adopts Nightingale Health’s blood analysis technology in regular health checks in occupational health – Aug 30, 2023
Nightingale Health rolls out remote blood collection kit for medical research and clinical trials – Aug 17, 2023
Conversion of Nightingale Health Plc’s EMP shares to Series B shares – Jul 06, 2023
Inside information: Update on Nightingale Health Plc’s business targets for financial year 2022 – 2023 – Jul 03, 2023
Inside information: Nightingale Health and Terveystalo sign letter of intent to expand strategic partnership – Jun 30, 2023
World's largest population study combining blood biomarkers and genetics demonstrates Nightingale Health's risk prediction models outperform genetic risk prediction in chronic diseases – Jun 15, 2023
Nightingale Health’s strategic collaboration with UK Biobank progresses: Biomarker results of additional 200,000 blood samples soon available to researchers globally – Jun 06, 2023
Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2023 – 2024 – May 31, 2023
Nightingale Health has received six patent approvals for its proprietary health risk detection platform – May 23, 2023
Maximilian LeRoux appointed as Chief Commercial Officer of Nightingale Health Plc – May 08, 2023
Nightingale Health Plc: Resolutions of the Extraordinary General Meeting and the Board of Directors’ organizational meeting – Apr 24, 2023
Livit by Nightingale Health reaches even more users – Mar 29, 2023
Nightingale Health Plc’s Auditor to Change – Mar 24, 2023
Nightingale Health Group’s Half-year report 1 July 2022 – 31 December 2022: Commercialization progressing in line with strategy – Mar 23, 2023
Nightingale Health Plc: Unaudited financial information in accordance with IFRS for the comparative half-year periods – Mar 22, 2023
Notice to the Extraordinary General Meeting of Nightingale Health Plc – Mar 17, 2023
Nightingale Health to publish half-year report for July – December 2022 on 23 March 2023 – Mar 15, 2023
Strategic collaboration in Estonia progresses: Nightingale Health completes the analysis of 200,000 Estonian Biobank samples – Mar 08, 2023
Nightingale Health Plc – Managers’ transactions – Olli Karhi – Feb 14, 2023
Nightingale Health combines genetics with its unique blood test results in Livit by Nightingale Health service – Feb 03, 2023
Inside information: Nightingale Health acquires worldwide license for blood self-collection device Velvet™ – Jan 31, 2023
Nightingale Health to open laboratory in the United Kingdom in 2023 – Jan 25, 2023
Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Dec 22, 2022
Nightingale Health Plc – Managers’ transactions – Leena Niemistö – Nov 29, 2022
Nightingale Health Plc – Managers’ transactions – Leena Niemistö – Nov 29, 2022
Change in the publication date of Nightingale Health Plc’s half-year financial report for the period 1 July – 31 December 2022 – Nov 17, 2022
Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc – Nov 17, 2022
Nightingale Health Plc – Managers’ transactions – Jeffrey Barrett – Nov 09, 2022
Nightingale Health’s Auditor’s Report for financial year 2021–2022 has been published – Nov 07, 2022
Nightingale Health Plc – Managers’ transactions – Teemu Suna – Oct 31, 2022
Nightingale Health’s Annual Report for financial year 2021–2022 has been published – Oct 27, 2022
Nightingale Health Plc: Adoption of International Financial Reporting Standards (IFRS) and unaudited financial information for the comparative period – Oct 27, 2022
Notice to the Annual General Meeting of Nightingale Health Plc – Oct 14, 2022
Independent study: Nightingale Health’s blood test shown to enhance health check-ups by predicting many diseases at once – Oct 07, 2022
Nightingale Health Plc Financial Statements Release 1 July 2021–30 June 2022 – Sep 29, 2022
Nightingale Health to publish Financial Statements Release for financial year July 2021–June 2022 on 29 September 2022 – Sep 23, 2022
Nightingale Health’s Board of Directors resolved on a change to the share-based incentive schemes – Aug 11, 2022
Update on Nightingale Health Plc’s business targets for financial year 2021 – 2022 – Jul 05, 2022
Resolutions of Nightingale Health Plc’s Extraordinary General Meeting – Jun 29, 2022
Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2022 – 2023 – Jun 15, 2022
Further landmark evidence released to showcase the ability of Nightingale Health’s technology to predict hundreds of diseases from a single blood sample – Jun 14, 2022
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Jun 10, 2022
Notice to the Extraordinary General Meeting of Nightingale Health Plc – Jun 08, 2022
Nightingale Health partners with Physitrack, expanding the availability of its preventative wellbeing service Livit to Germany, the UK and in the Nordics – Jun 08, 2022
Analysis: Nightingale Health’s net impact among the top 7 percent of companies worldwide – May 31, 2022
Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares – May 19, 2022
Nightingale Health launches consumer service Livit by Nightingale Health utilizing its at-home testing solution – Mar 31, 2022
Nightingale’s Board of Directors resolved on new share-based incentive plans – Mar 18, 2022
Nightingale Health Group’s Half-year report 1 July 2021 – 31 December 2021: Progressing faster than expected in line with strategy – Feb 24, 2022
Nightingale to publish half-year report for July – December 2021 on 24 February 2022 – Feb 16, 2022
Conversion of Nightingale Health Plc’s Series A shares to Series B shares – Feb 08, 2022
Nightingale has completed the acquisition of Finnish genetic testing company Negen – Feb 03, 2022
Nightingale’s information security management certification continued with outstanding results in surveillance audit – Jan 20, 2022
Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis – Jan 18, 2022
Nightingale Home service launched with major Finnish pharmacy chain Yliopiston Apteekki – Dec 22, 2021
Nightingale’s preventative health service launched at Shin-Oyama City Hospital in Japan – Dec 21, 2021
Nightingale expands its Japan laboratory – Dec 17, 2021
Nightingale’s corporate health service piloted at Mitsui headquarters in Tokyo – Nov 18, 2021
Nightingale launches Nightingale Home and Nightingale Pro service models – Nov 15, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Nov 08, 2021
Tuukka Paavola appointed as Chief Financial Officer of Nightingale Health Plc – Nov 02, 2021
Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares – Oct 29, 2021
Resolutions of Nightingale Health Plc’s Annual General Meeting and Board of Directors – Oct 28, 2021
Recording of event: An hour with Nightingale – Oct 28, 2021
Nightingale and BioBank Japan to realise personalised medicine and preventative health in Japan – Oct 28, 2021
Nightingale and major Finnish pharmacy chain Yliopiston Apteekki enter into nation-wide distribution partnership of Nightingale’s at-home testing solution – Oct 27, 2021
Invitation to event: An hour with Nightingale – Oct 18, 2021
Fimea inspected Nightingale’s regulatory compliance with the requirements for manufacturer of medical device – Oct 14, 2021
Nightingale and Terveystalo launch a new well-being membership – Oct 13, 2021
Nightingale receives CE marking for its at-home blood collection kit – Oct 07, 2021
Notice to the Annual General Meeting of Nightingale Health Plc – Oct 01, 2021
Nightingale’s Annual Report for financial year 2020–2021 published – Oct 01, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Sep 17, 2021
Nightingale Health Plc Financial Statements Release 1 July 2020 – 30 June 2021 – Sep 15, 2021
Nightingale to publish Financial Statements Release for financial year July 2020–June 2021 on 15 September 2021 – Sep 07, 2021
Jeffrey Barrett appointed as Chief Scientific Officer of Nightingale Health Plc – Aug 30, 2021
Nightingale Health acquires German digital health company Yolife GmbH – Jul 09, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Jul 06, 2021
Nightingale Health quarterly summary of achieved key milestones and reiteration of near-term business targets – Jul 01, 2021
Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment – Jun 29, 2021
Nightingale successfully completes the first phase of its at-home blood testing pilot – Jun 23, 2021
Nightingale restructures its Management Team and establishes strategic partnership with Reaktor – May 04, 2021
Reaktor becomes strategic partner of Nightingale to accelerate international growth – May 04, 2021
Nightingale Health signed service agreement for health and well-being services in Japan – Apr 29, 2021
Nightingale Health Plc and Terveystalo have entered into strategic partnership agreement – Apr 22, 2021
Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan – Apr 09, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Apr 07, 2021
The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register – Mar 31, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Mar 30, 2021
Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering – Mar 25, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Mar 25, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Mar 24, 2021
Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares – Mar 23, 2021
Nightingale Health Plc – Managers’ transactions – Timo Soininen – Mar 23, 2021
Nightingale Health Plc – Managers’ transactions – Teemu Suna – Mar 23, 2021
Nightingale Health Plc – Managers’ transactions – Kari Niemistö – Mar 23, 2021
Nightingale Health Plc – Managers’ transactions – Leena Niemistö – Mar 23, 2021
The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021 – Mar 18, 2021
Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued – Mar 16, 2021
Nightingale Health Plc comments on the media coverage on its initial public offering – Mar 15, 2021
Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering – Mar 08, 2021
Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland – Mar 08, 2021
Nightingale intends to launch an initial public offering and listing on Nasdaq First North Growth Market Finland – Feb 19, 2021
Nightingale Health Accelerates the Availability of Its At-Home Blood Testing Solution by Launching an Early-Access Pilot for 10,000 Consumers in Finland – Feb 17, 2021
Nightingale Health and Estonian Biobank Agree Strategic Collaboration Aiming to Work Towards Estonian Biobank’s Nationwide Early Disease Prevention in Estonia – Feb 04, 2021
Nightingale Health secured funding of EUR 8.8 million, Leena Niemistö appointed as member of the Board – Jan 20, 2021
Timo Soininen joins Nightingale as Chairman of the Board – Dec 17, 2020
Nightingale Health appoints lead financial advisor to explore different financing options – Oct 27, 2020
Nightingale to roll-out novel preventative solution for COVID-19 enabling safe returns to work post lockdowns – Jul 06, 2020
Nightingale Health’s blood analysis shows great promise for preventative COVID-19 and Pneumonia Risk Detection – Jun 15, 2020
World-leading population-health researchers join Nightingale’s Scientific Advisory Board – Feb 10, 2020
Mr. Yrjö Närhinen becomes an Investor and Strategic Advisor for Nightingale Health to accelerate its international growth – Jan 31, 2020
Nightingale’s advanced blood-testing for consumers begins service in Helsinki – Jan 30, 2020
Nightingale Health takes first step to bring preventative health for 8 billion – rolls out consumer blood testing and mobile app – Nov 21, 2019
Nightingale Health Opens EUR 50-80M Private Placement Round with Carnegie as its Advisor to Bring Nightingale’s Preventative Health Technology to International Markets – Nov 21, 2019
Nightingale Health Announces Strategic Partnership with Kirin and Mitsui to Bring Nightingale’s Internationally Recognised Blood-Testing Services to the Japanese Market – Nov 15, 2019
Nightingale Health and Imperial College London to investigate new indicators of diabetes in the South Asian population – Nov 04, 2019
Research Institute for Olympic Sports collaborates with Nightingale to enhance athletes’ health and performance – Sep 18, 2019
Nightingale Health expands service coverage to the United States – Jun 07, 2019
Nightingale Health collaborates with National University of Singapore to realise the prevention of chronic diseases in South East Asia – May 08, 2019
Nightingale Health receives laboratory accreditation for clinical services – Apr 16, 2019
Nightingale Health to receive EUR 20 million EU-financing to herald a new era of chronic disease prevention – Jan 18, 2019
Finnish blood testing scale-up and health service provider introduce healthcare for the 21 st century – connecting molecular medicine with lifestyle habits – Dec 02, 2018
New technology links chronic inflammation with increased risk of a wide range of diseases and shorter lifespan – Nov 15, 2018
Nightingale chosen as Nordics' Best Health Tech Startup – Nov 08, 2018
Nightingale wins Finnish Startup of the Year Award – Sep 27, 2018
Nightingale Health to provide biomarker analysis for the world’s largest blood-based prospective cohort study in Latin America – Sep 04, 2018
Nightingale Health and UK Biobank announce major initiative to analyse half a million blood samples to facilitate global medical research – Jun 21, 2018
Nightingale Health expands CE marked blood biomarker service with urine, cerebrospinal fluid and umbilical cord blood services – May 15, 2018
Nightingale Health and THL Biobank to accelerate personalized medicine by analyzing 40,000 blood samples – Mar 12, 2018
Nightingale Health announces strategic collaboration with PerkinElmer – Mar 01, 2018
Nightingale Health awarded “Health Innovation” of the Year – Jan 31, 2018
Nightingale Health Shortlisted for Finnish Health Awards 2018 – Dec 11, 2017
Nightingale Awarded as One of the Most Innovative Biotech SMEs in Europe – Nov 24, 2017
Cutting-edge blood analysis service to realize use in healthcare – Oct 05, 2017
Finnish biomedical start-up Nightingale Health obtains CE mark for blood analysis platform – Jul 03, 2017
Oxford University’s Nuffield Department of Population Health and Nightingale Health announce agreement for comprehensive metabolic biomarker profiling – May 08, 2017
Healthcare start up Nightingale invited to solve world’s biggest health problem with the UN and MIT – Feb 17, 2017
Pioneering Healthcare Company changes name from Brainshake to “Nightingale Health” – Feb 17, 2017
Blood Analysis Company Brainshake Closes Funding of €2M Three Months after First Round – Oct 03, 2016
Brainshake Closes €3.5M to Advance Regulatory Approval of Blood Analysis Service – Sep 14, 2016